The Releaf Cannabis Blog

What 24 cancer patients told us about medical cannabis for symptom relief: findings from Releaf's 2025 UK patient survey

Releaf's 2025 UK Medical Cannabis Patient Survey is the largest survey of active UK medical cannabis patients ever conducted. Of the 1,669 respondents, 24 selected cancer-related as their primary condition category. All 24 reported an improvement in quality of life, 83.3% rated their treatment extremely, very, or moderately effective, 83.3% experienced no side effects, and 95.8% would recommend medical cannabis to others. Here is what these patients told us about managing their symptoms alongside conventional oncology care.

7 min read

03.06.2026

Sam North

114 patients picked up the phone: Inside the first four months of Releaf Protect legal helpline data

In the first four months of 2026, 114 Releaf patients picked up the phone to the Releaf Protect legal helpline. Across employment disputes, criminal procedure questions, and roadside concerns, the data reveals the everyday reality of being a legal medical cannabis patient in a system still catching up with the law.

7 min read

28.05.2026

Sam North

Decoding Cannabis: what the first placebo-controlled cannabis migraine trial means for patients in 2026

The first randomised, placebo-controlled trial of vaporised cannabis for migraine attacks has finally been published. Researchers at UC San Diego compared THC, CBD, a balanced combination, and placebo across 247 treated migraines. The balanced ratio came out clearly ahead, with sustained benefit at 24 and 48 hours and no serious adverse events. We unpack what the trial proves, where it falls short, and how the results sit alongside Releaf's UK patient survey data on medical cannabis for migraine.

8 min read

26.05.2026

Sam North

What the UK’s largest active medical cannabis patient survey revealed about gastroenterological conditions

96.1% of UK gastroenterological patients surveyed in Releaf’s 2025 medical cannabis survey said their prescribed medical cannabis treatment was effective at managing their symptoms, 97.4% reported improvements in their overall quality of life, and 98.7% said they would recommend medical cannabis treatment to someone with a similar qualifying condition.

8 min read

19.05.2026

Sam North

Chronic Pain

Mental Health

Sleeping Disorders

Neurological

Women's Health

Gastroenterological

Cancer Support

Chronic Pain

Mental Health

Sleeping Disorders

Neurological

Women's Health

Gastroenterological

Cancer Support

Releaf Blog

Latest

The treatment option 1.77 million Brits source illegally: UK’s legal medical cannabis access gap explained

Quick reads

What to know before starting medical cannabis treatment with Releaf

What are the qualifying conditions for a UK medical cannabis prescription?

Medical cannabis prices UK: Complete cost breakdown

Medical cannabis and employment: what you need to know

Indica vs Sativa differences: what the newest research reveals about these classifications

What 24 cancer patients told us about medical cannabis for symptom relief: findings from Releaf's 2025 UK patient survey

114 patients picked up the phone: Inside the first four months of Releaf Protect legal helpline data

Decoding Cannabis: what the first placebo-controlled cannabis migraine trial means for patients in 2026

What the UK’s largest active medical cannabis patient survey revealed about gastroenterological conditions

Featured in

Chronic Pain

Mental Health

Sleeping Disorders

Neurological

Women's Health

Gastroenterological

Cancer Support

Chronic Pain

Mental Health

Sleeping Disorders

Neurological

Women's Health

Gastroenterological

Cancer Support

Releaf Blog

Latest

Quick reads

Articles